Merck & Co. vs Lilly (Eli)
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global pharma anchored by Keytruda ($25B cancer drug); $63.6B FY2024 revenue; Gardasil China collapse 2024 ($2B loss); Winrevair PAH approval 2024; Keytruda patent cliff 2028-2030 is defining challenge.
About
Merck & Co. is one of the world's largest research-driven pharmaceutical companies, founded in the United States in 1891 as a subsidiary of the German Merck KGaA and now an independent American company headquartered in Rahway, New Jersey, trading on NYSE (MRK). The company generated approximately $63.6 billion in revenues for FY2024 under CEO Robert Davis, anchored by Keytruda (pembrolizumab)—the world's best-selling cancer drug—which generated approximately $25 billion in global sales as the dominant checkpoint inhibitor immunotherapy across over 40 approved tumor indications including lung cancer, melanoma, bladder cancer, cervical cancer, and dozens more. Merck's animal health subsidiary, Merck Animal Health, is a global leader in livestock and companion animal medicines including Bravecto (flea/tick prevention) and contributes approximately $6 billion in revenues.
Indianapolis pharma leader (NYSE: LLY) $45.1B FY2024 revenue (+32%); Mounjaro $11.4B + Zepbound $4.9B tirzepatide GLP-1, oral orforglipron Phase 3, $18B manufacturing expansion competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Health Care component — discovering, developing, and commercializing medicines across diabetes, obesity, oncology, immunology, and neuroscience through approximately 43,000 employees worldwide. In fiscal year 2024, Eli Lilly reported revenues of $45.1 billion (+32% year-over-year) — driven by the historic commercial launch of Mounjaro (tirzepatide for type 2 diabetes, $11.4B revenue) and Zepbound (tirzepatide for obesity and obstructive sleep apnea, $4.9B revenue) — making Eli Lilly one of the fastest-growing large pharmaceutical companies in history and elevating its market capitalization above $700 billion at peak 2024 valuation, briefly making Lilly the most valuable healthcare company globally. CEO Dave Ricks' strategic investment in tirzepatide manufacturing capacity — committing $18+ billion to new US manufacturing sites in Indiana, Wisconsin, and North Carolina — reflects Lilly's execution of unprecedented pharmaceutical demand that has consistently outpaced supply since Mounjaro's 2022 approval and Zepbound's 2023 FDA approval for obesity. The GLP-1/GIP dual agonist mechanism (tirzepatide activates both GLP-1 and GIP incretin receptors, versus semaglutide's single GLP-1 activation) produces superior efficacy results — SURMOUNT-1 trial showing 22.5% average body weight loss with tirzepatide versus 15% with semaglutide (Ozempic/Wegovy) — establishing tirzepatide as the most effective approved obesity pharmacotherapy.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.